Company Performance Metrics
- Mahati Munikoti: Senior Research Scientist
Karyon Bio is a next-generation SaaS company at the intersection of biotechnology and AI. Our flagship platform creates digital twins of the liver (LiverTwin™), enabling early detection, risk stratification, and personalized treatment of fatty liver disease (MASLD/MASH) and related metabolic disorders.
The platform unifies multi-omics,
medical imaging (ultrasound, MRI, CT), EHR/clinical data, and lifestyle/demographics into a scalable pipeline. Using advanced graph transformers, multimodal AI, and explainable techniques, Karyon Bio discovers novel biomarkers and translates them into non-invasive, clinically usable diagnostics.
Delivered as a SaaS solution, our product—LiverTwin™ (digital-twin engine) —plugs seamlessly into hospital IT systems and payer workflows via FHIR-compliant APIs. Deployed on HIPAA-secure, multi-cloud environments (AWS, Oracle Cloud, NVIDIA DGX, Google Vertex AI), Karyon Bio supports global hospital networks, insurers, and pharmaceutical R&D.
By shifting diagnosis from late-stage to early-stage, Karyon Bio reduces healthcare costs, improves outcomes, and opens new pathways for precision medicine—scaling across the US, India, Saudi Arabia, Hong Kong, and the UK.
